TABLE 1.
Efficacy Parameters for Available Efficacy Profiles
| Efficacy profile | Timepoint | Virologic suppression | Baseline CD4 cell count | Change in CD4 cell count | Monthly discontinuation | |
|---|---|---|---|---|---|---|
| Virologic discontinuation | Non-virologic discontinuation | |||||
| Mean (SE), % | Mean (SD) | Mean (SD) | Mean (SE) | |||
| DTG/3TC (naive)8 | Wk 0-48 | 91.48 (1.04) | 462.00 (219.3) | 224.10 (172.2) | 0.0023 (0.0018) | 0.0056 (0.0028) |
| Wk 48-96 | 86.03 (1.04) | 687.90 (270.7) | 44.90 (16.5) | 0.0003 (0.0006) | 0.0045 (0.0025) | |
| DTG + TDF/FTC8 | Wk 0-48 | 93.31 (0.93) | 462.00 (219.3) | 217.10 (190.6) | 0.0015 (0.0015) | 0.0047 (0.0025) |
| Wk 48-96 | 89.53 (0.93) | 682.60 (292.0) | 40.60 (17.4) | 0.0001 (0.0004) | 0.0032 (0.0021) | |
| DTG/ABC/3TC17 | Wk 0-48 | 91.28 (1.05) | 462.00 (219.3) | 254.20 (172.2) | 0.0025 (0.0018) | 0.0047 (0.0025) |
| Wk 48-96 | 86.03 (1.05) | 716.14 (270.7) | −16.80 (16.5) | 0.0019 (0.0012) | 0.0051 (0.0019) | |
| DRV/c/TAF/FTCa,17 | Wk 0-48 | 84.38 (1.36) | 462.00 (219.3) | 216.60 (172.2) | 0.0091 (0.0034) | 0.0047 (0.0025) |
| Wk 48-96 | 68.03 (1.03) | 678.58 (270.7) | NA | 0.0019 (0.0012) | 0.0051 (0.0019) | |
| BIC/TAF/FTC17 | Wk 0-48 | 90.58 (1.09) | 462.00 (219.3) | 258.80 (172.2) | 0.0031 (0.0021) | 0.0047 (0.0025) |
| Wk 48-96 | 86.03 (1.05) | 720.76 (270.7) | −32.1 (16.5) | 0.0019 (0.0012) | 0.0051 (0.0019) | |
| DTG/3TC (experienced)10 | Wk 0-48 | 93.22 (1.31) | 702.00 (289.2) | 29.20 (179.5) | 0.0002 (0.0008) | 0.0061 (0.0040) |
| cTBR10 | Wk 0-48 | 93.01 (1.31) | 726.00 (273.5) | 2.90 (178.6) | 0.0005 (0.0011) | 0.0060 (0.0040) |
| Treatment experienced: stable switchb,19,20 | All periods | 88.98 (1.26) | 540.00 (232.5) | 69.25 (149.1) | 0.0053 (0.0003) | 0.0079 (0.0004) |
| Treatment experienced: failing switchc,21 | All periods | 73.78 (3.69) | 168.70 (155.1) | 176.40 (149.3) | 0.0165 (0.0008) | 0.0024 (0.0001) |
| Salvage 1d,22,23 | All periods | 71.04 (3.55) | 151.00 (141.0) | 119.00 (132.3) | NA | NA |
| Salvage 2d,24,25 | All periods | 60.60 (3.03) | 151.00 (141.0) | 111.00 (146.3) | NA | NA |
| Salvage 3d,24,25 | All periods | 50.80 (2.54) | 151.00 (141.0) | 71.00 (100.8) | NA | NA |
a The efficacy profile assigned to the DRV/c/TAF/FTC profile is informed by DRV/r/TDF/FTC where cobicistat-boosted darunavir is assumed equally efficacious as ritonavir-boosted darunavir and TAF/FTC is assumed equally efficacious to TDF/FTC
b Virologic suppression taken from Antinori et al.; weighted mean of included studies reporting variable of interest in Baril et al used for CD4 cell count
c Weighted mean of included studies reporting variable of interest
d Based on the raltegravir arm of the clinical trial
3TC = lamivudine; ABC = abacavir; BIC = bictegravir; CD4 = cluster of differentiation 4; cTBR = continuation of TAF-based regimen; DRV/c = cobicistat-boosted darunavir; DTG = dolutegravir; FTC = emtricitabine; NA = not applicable; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; SD = standard deviation; SE = standard error; Wk = week.